OTCMKTS:MRMD MariMed (MRMD) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free MRMD Stock Alerts $0.29 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$0.28▼$0.3050-Day Range$0.20▼$0.3252-Week Range$0.20▼$0.55Volume110,790 shsAverage Volume460,658 shsMarket Capitalization$108.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get MariMed alerts: Email Address Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> About MariMed Stock (OTCMKTS:MRMD)MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.Read More MRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRMD Stock News HeadlinesMay 8, 2024 | globenewswire.comMariMed Reports First Quarter 2024 EarningsMay 8, 2024 | americanbankingnews.comMariMed (OTCMKTS:MRMD) Shares Up 1.9%May 8, 2024 | Smallcaps Daily (Ad)The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.April 30, 2024 | msn.comCannabis Industry Leaders React To DEA's Historic Move To Reschedule CannabisApril 30, 2024 | finance.yahoo.comStatement From MariMed CEO And President Jon Levine Regarding The Drug Enforcement Administration’s Decision To Recategorize Cannabis To Schedule IIIApril 30, 2024 | globenewswire.comStatement From MariMed CEO And President Jon Levine Regarding The Drug Enforcement Administration's Decision To Recategorize Cannabis To Schedule IIIApril 26, 2024 | finance.yahoo.comMariMed closes acquisition of a dispensary in Illinois marking the company’s 5th in that stateApril 21, 2024 | msn.comCannabis Investors Share 'Chips Make Chunks' Wisdom For Business Expansion At Benzinga ConferenceMay 8, 2024 | Smallcaps Daily (Ad)The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.April 17, 2024 | benzinga.com'A F—ed-Up Situation,' Says MariMed CCO About How State Regulations Complicate Cannabis Edibles StrategyApril 13, 2024 | uk.investing.comMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company's Fifth Illinois DispensaryApril 11, 2024 | msn.comMariMed Is On A Roll: Partners With Two Iconic Music Venues In Boston, Acquires Another Illinois Cannabis DispensaryApril 11, 2024 | finance.yahoo.comMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company’s Fifth Illinois DispensaryApril 11, 2024 | finance.yahoo.comMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company’s Fifth Illinois DispensaryApril 11, 2024 | globenewswire.comMariMed Closes Acquisition of Thrive Dispensary in Casey, The Company's Fifth Illinois DispensaryApril 10, 2024 | bizjournals.comMass. cannabis firm sponsors MGM Music Hall, House of BluesApril 10, 2024 | globenewswire.comMariMed Partners with Iconic Boston Music VenuesApril 10, 2024 | globenewswire.comMariMed Partners with Iconic Boston Music VenuesApril 9, 2024 | finanznachrichten.deMariMed Inc.: MariMed Closes Acquisition of Second Maryland DispensaryApril 9, 2024 | globenewswire.comMariMed Closes Acquisition of Second Maryland DispensaryApril 8, 2024 | globenewswire.comMariMed Announces First Quarter 2024 Earnings DateMarch 27, 2024 | msn.com'Unsexy' Alternative, Operating Within Constraints, Consistency & Love: 3 Experts On Making Cannabis Businesses Self-SustainableMarch 12, 2024 | globenewswire.comA Bigger Dispensary Opens in the Town of “Big Things” as MariMed Opens Larger, Permanent Thrive Dispensary in Casey, IllinoisMarch 9, 2024 | seekingalpha.comMariMed Inc. (MRMD) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comMariMed Inc. (PNK:MRMD) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finanznachrichten.deMariMed Inc.: MariMed Reports Fourth Quarter and Full Year 2023 EarningsMarch 7, 2024 | msn.comMariMed Reports 'Another Year Of Strong Operational And Financial Performance' And More To Come In 2024See More Headlines Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolOTCMKTS:MRMD CUSIPN/A CIK1522767 Webmarimedadvisors.com Phone(617) 795-5140FaxN/AEmployees643Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,030,000.00 Net Margins-10.79% Pretax Margin-4.44% Return on Equity-1.84% Return on Assets-0.72% Debt Debt-to-Equity Ratio0.97 Current Ratio1.67 Quick Ratio0.85 Sales & Book Value Annual Sales$148.60 million Price / Sales0.74 Cash Flow$0.03 per share Price / Cash Flow10.07 Book Value$0.19 per share Price / Book1.55Miscellaneous Outstanding Shares375,130,000Free Float298,041,000Market Cap$110.66 million OptionableNot Optionable Beta2.75 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Jon R. Levine (Age 59)Co-Founder, CEO, Interim CFO, President, Secretary, Treasurer & Director Comp: $390.5kMr. Timothy Shaw (Age 46)Chief Operating Officer Comp: $346.62kMr. Jonathan W. Rider (Age 59)Chief Information Officer Mr. Steve Wayne WestVice President of Investor RelationsMr. Howard SchacterChief Communications OfficerMr. Ryan CrandallChief Revenue OfficerMr. Charles Holt FinnieChief Strategy OfficerMore ExecutivesKey CompetitorsJushiOTCMKTS:JUSHFFitLife BrandsNASDAQ:FTLFBright GreenNASDAQ:BGXXMediWoundNASDAQ:MDWDNatural Alternatives InternationalNASDAQ:NAIIView All Competitors MRMD Stock Analysis - Frequently Asked Questions How have MRMD shares performed in 2024? MariMed's stock was trading at $0.2748 at the start of the year. Since then, MRMD stock has increased by 5.6% and is now trading at $0.2902. View the best growth stocks for 2024 here. Are investors shorting MariMed? MariMed saw a drop in short interest in April. As of April 15th, there was short interest totaling 15,300 shares, a drop of 55.5% from the March 31st total of 34,400 shares. Based on an average daily volume of 805,900 shares, the short-interest ratio is currently 0.0 days. View MariMed's Short Interest. How were MariMed's earnings last quarter? MariMed Inc. (OTCMKTS:MRMD) released its quarterly earnings data on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $33.21 million for the quarter. MariMed had a negative trailing twelve-month return on equity of 1.84% and a negative net margin of 10.79%. What guidance has MariMed issued on next quarter's earnings? MariMed issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $156.0 million-$159.0 million, compared to the consensus revenue estimate of $157.4 million. What other stocks do shareholders of MariMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other MariMed investors own include KushCo (KSHB), Organigram (OGI), Auxly Cannabis Group (CBWTF), CNBX Pharmaceuticals (CNBX), Supreme Cannabis (SPRWF), Pennsylvania Real Estate Investment Trust (PEI), GB Sciences (GBLX), Medical Marijuana (MJNA) and Smart Cannabis (SCNA). How do I buy shares of MariMed? Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MRMD) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MariMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.